{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T02:51:17Z","timestamp":1792464677375,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T00:00:00Z","timestamp":1649376000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007659","name":"Bayer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.critrevonc.2022.103678","type":"journal-article","created":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T20:46:07Z","timestamp":1649105167000},"page":"103678","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Clinical studies of extended-half-life recombinant FVIII products for prophylaxis in adults and children: A critical review from the physician's perspective"],"prefix":"10.1016","volume":"174","author":[{"given":"Cedric","family":"Hermans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark T.","family":"Reding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Astermark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Klamroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Elisa","family":"Mancuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.critrevonc.2022.103678_bib1","first-page":"314","article-title":"Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the future","volume":"12","author":"Jimenez-Yuste","year":"2014","journal-title":"Blood Transfus."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103678_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/jcm6040039","article-title":"Outcome of Clinical Trials with New Extended Half-Life FVIII\/IX Concentrates","volume":"6","author":"Mancuso","year":"2017","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.critrevonc.2022.103678_bib3","unstructured":"European Medicines Agency, Summary of Product Characteristics (ELOCTA). [cited 2020a June]; Available from: \u3008https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/elocta-epar-product-information_en.pdf\u3009."},{"key":"10.1016\/j.critrevonc.2022.103678_bib4","unstructured":"European Medicines Agency, Summary of Product Characteristics (Jivi). [cited 2020b June]; Available from: \u3008https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/jivi-epar-product-information_en.pdf\u3009."},{"key":"10.1016\/j.critrevonc.2022.103678_bib5","unstructured":"European Medicines Agency, Summary of Product Characteristics (Adynovate). [cited 2020c June]; Available from: \u3008https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/adynovi-epar-product-information_en.pdf\u3009."},{"key":"10.1016\/j.critrevonc.2022.103678_bib6","unstructured":"European Medicines Agency, Summary of Product Characteristics (Esperoct). [SmPC] [cited 2020d June]; Available from: \u3008https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/esperoct-epar-product-information_en.pdf\u3009."},{"key":"10.1016\/j.critrevonc.2022.103678_bib7","unstructured":"FDA, 2016, Adynovate Package Insert, FDA, Editor."},{"key":"10.1016\/j.critrevonc.2022.103678_bib8","unstructured":"FDA, 2018, Jivi Package Insert, FDA, Editor."},{"key":"10.1016\/j.critrevonc.2022.103678_bib9","unstructured":"FDA, 2019a, Esperoct Package Insert, FDA, Editor."},{"key":"10.1016\/j.critrevonc.2022.103678_bib10","unstructured":"FDA, 2019b, Eloctate Package Insert, FDA, Editor."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103678_bib11","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/blood-2013-10-529974","article-title":"Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A","volume":"123","author":"Mahlangu","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103678_bib12","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jth.13597","article-title":"Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII","volume":"15","author":"Reding","year":"2017","journal-title":"J. Thromb. Haemost."},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103678_bib13","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood-2015-03-630897","article-title":"Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A","volume":"126","author":"Konkle","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103678_bib14","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1160\/TH16-06-0444","article-title":"Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A","volume":"117","author":"Giangrande","year":"2017","journal-title":"Thromb. Haemost."},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103678_bib15","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/jth.12911","article-title":"Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A","volume":"13","author":"Young","year":"2015","journal-title":"J. Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103678_bib16","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1111\/hae.13963","article-title":"PROTECT VIII Kids: BAY 94-9027 (PEGylated Recombinant Factor VIII) safety and efficacy in previously treated children with severe haemophilia A","volume":"26","author":"Santagostino","year":"2020","journal-title":"Haemophilia"},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103678_bib17","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/hae.13119","article-title":"Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A","volume":"23","author":"Mullins","year":"2017","journal-title":"Haemophilia"},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103678_bib18","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1160\/TH17-03-0166","article-title":"Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A","volume":"117","author":"Meunier","year":"2017","journal-title":"Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103678_bib19","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/hae.13953","article-title":"Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study","volume":"26","author":"Nolan","year":"2020","journal-title":"Haemophilia"},{"issue":"S1","key":"10.1016\/j.critrevonc.2022.103678_bib20","first-page":"15","article-title":"BAY 94\u20139027 provides effective long\u2010term prophylaxis in pediatric patients: interim results of the PROTECT VIII Kids extension study. [WFH 2018 abstract]","volume":"25","author":"Kenet","year":"2018","journal-title":"Haemophilia"},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103678_bib21","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/hae.13853","article-title":"BAY 94-9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results","volume":"25","author":"Lalezari","year":"2019","journal-title":"Haemophilia"},{"issue":"Supplement 1","key":"10.1016\/j.critrevonc.2022.103678_bib22","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1182\/blood-2018-99-114659","article-title":"Efficacy and Safety of Bay 94-9027 Is Sustained for 5 Years: Outcomes in 33 Patients in the Protect VIII Extension Study","volume":"132","author":"Reding","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103678_bib23","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/hae.13712","article-title":"Once-weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8-GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial)","volume":"25","author":"Curry","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.critrevonc.2022.103678_bib24","series-title":"Haemophilia","first-page":"1","article-title":"WFH Guidelines for the Management of Hemophilia","author":"Srivastava","year":"2020"},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103678_bib25","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1182\/asheducation-2016.1.657","article-title":"Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches","volume":"2016","author":"Meeks","year":"2016","journal-title":"Hematology"},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103678_bib26","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1182\/asheducation-2016.1.648","article-title":"What is the role of an extended half-life product in immune tolerance induction in a patient with severe hemophilia A and high-titer inhibitors?","volume":"2016","author":"Janbain","year":"2016","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103678_bib27","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/2040620718796429","article-title":"Practical aspects of extended half-life products for the treatment of haemophilia","volume":"9","author":"Lambert","year":"2018","journal-title":"Ther. Adv. Hematol."},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103678_bib28","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1007\/s00277-019-03747-2","article-title":"Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A","volume":"98","author":"Shah","year":"2019","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.critrevonc.2022.103678_bib29","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1007\/s00277-020-04280-3","article-title":"Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A","volume":"99","author":"Solms","year":"2020","journal-title":"Ann. Hematol."},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103678_bib30","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1111\/jth.14469","article-title":"Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?","volume":"17","author":"Carcao","year":"2019","journal-title":"J. Thromb. Haemost."},{"issue":"8","key":"10.1016\/j.critrevonc.2022.103678_bib31","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1177\/2040620718784830","article-title":"The role of patient and healthcare professionals in the era of new hemophilia treatments in developed and developing countries","volume":"9","author":"Nossair","year":"2018","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.critrevonc.2022.103678_bib32","unstructured":"Bayer, A Trial Investigating Safety and Efficacy of Treatment With BAY94\u20139027 in Severe Hemophilia A (PROTECT-VIII). 2020: clinicaltrials.gov."},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2022.103678_bib33","article-title":"Efficacy and Safety of BAY 94-9027 Prophylaxis for \u22655 Years: Outcomes in 36 Patients from the PROTECT VIII Extension Study","volume":"4","author":"Holme","year":"2020","journal-title":"Res. Pract. Thromb. Haemost."},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2022.103678_bib34","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2020-140303","article-title":"BAY 94-9027 Provides Safe and Effective Long-Term Prophylaxis in Pediatric Patients: Results from the PROTECT VIII Kids Extension Study","volume":"136","author":"Ahuja","year":"2020","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.critrevonc.2022.103678_bib35","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1182\/blood-2019-123947","article-title":"Improvement in Quality of Life Outcomes and Bleeding Rates among Patients Switching from On-demand FVIII to Prophylactic BAY 94-9027 in the PROTECT VIII Study","volume":"134","author":"Ducore","year":"2019","journal-title":"Blood"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842822001020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842822001020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:42:26Z","timestamp":1760902946000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842822001020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":35,"alternative-id":["S1040842822001020"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103678","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical studies of extended-half-life recombinant FVIII products for prophylaxis in adults and children: A critical review from the physician's perspective","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103678","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103678"}}